Haas Jason — SEC Form 4 filings
SEC reporting owner CIK 1883821. 10 Form 4 filings on record with FilingPulse; latest filed 2026-08-14.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-04-02 to 2026-08-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 2 filings — 101,000 shares, $181,240 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 4 legs across 3 filings — 151,402 shares, $3,770,362 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 7,138 shares @ $292.81 ($2,090,062) in LIGAND PHARMACEUTICALS INC, filed 2026-08-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC (LGND) | Director | 5 | — | 3 legs · 13,599 sh · $3,741,382 | 12 |
| Syros Pharmaceuticals, Inc. (SYRS) | Chief Financial Officer | 4 | 3 legs · 100,000 sh · $161,240 | 1 leg · 137,803 sh · $28,980 | 8 |
| Odyssey Therapeutics, Inc. (ODTX) | Chief Financial Officer | 1 | 1 leg · 1,000 sh · $20,000 | — | — |
Form 4 filings — Haas Jason
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 6,138 @ $51.56 · Sale (S): 7,138 @ $292.81 · Option exercise (M): 6,138 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 3,000 @ $51.56 · Option exercise (M): 1,000 @ $51.56 · Sale (S): 3,000 @ $255.01 · Sale (S): 3,461 @ $256.08 · Option exercise (M): 3,000 (derivative) @ $0 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 836 @ $0 · Grant/award (A): 2,938 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Odyssey Therapeutics, Inc. (ODTX) | Purchase (P): 1,000 @ $20 | EDGAR |
| 2025-06-10 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 1,209 @ $0 · Grant/award (A): 5,783 (derivative) @ $0 | EDGAR |
| 2024-11-20 | 4 | Syros Pharmaceuticals, Inc. (SYRS) | Sale (S): 137,803 @ $0.21 | EDGAR |
| 2024-11-04 | 4 | Syros Pharmaceuticals, Inc. (SYRS) | Option exercise (M): 18,875 · Tax withholding (F): 5,624 @ $2.09 · Option exercise (M): 18,875 (derivative) @ $0 | EDGAR |
| 2024-09-12 | 4 | Syros Pharmaceuticals, Inc. (SYRS) | Purchase (P): 35,363 @ $1.55 · Purchase (P): 19,293 @ $1.58 · Purchase (P): 45,344 @ $1.68 | EDGAR |
| 2024-06-18 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 1,252 @ $0 · Grant/award (A): 5,444 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Syros Pharmaceuticals, Inc. (SYRS) | Option exercise (M): 2,000 · Option exercise (M): 13,333 · Tax withholding (F): 4,732 @ $5.12 · Option exercise (M): 2,000 (derivative) @ $0 · Option exercise (M): 13,333 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1883821 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →